GSK Press Releases - EIN Presswire - Press Release Distribution Service

Published on April 27, 2012 - 12:10 GMT

GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)

Issued: Friday 27 April 2012, London UK GlaxoSmithKline plc (GSK) announced today that the European Commission has granted marketing authorisation for Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine) for active immunisation against …

Distribution channels: Companies

Published on April 26, 2012 - 23:13 GMT

FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma

Issued: Thursday 26 April 2012, Philadelphia GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient ® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who …

Distribution channels: Companies

Published on April 26, 2012 - 13:12 GMT

Children in Ghana to be vaccinated against diarrhoeal disease with the introduction of GSK’s Rotarix™ vaccine

Issued: Thursday 26 April 2012, London UK - Agreement finalised to supply up to 132 million doses of Rotarix at an affordable price to GAVI* over 5 years - Ghana becomes the first African country to introduce simultaneously two new vaccines through …

Distribution channels: Companies

Published on April 26, 2012 - 08:10 GMT

GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry

Issued: Thursday 26 April 2012, London - Innovative carbon neutral laboratory to be established on University Campus GlaxoSmithKline (GSK) and the University of Nottingham today formalised a collaboration to establish a new laboratory to …

Distribution channels: Companies

Published on April 25, 2012 - 11:10 GMT

Results announcement for the first quarter 2012

Issued: Wednesday 25 April 2012, London UK - Sales growth of +2% CER - Further R&D delivery, operational leverage and continued returns to shareholders - Core EPS 27.3p (+7%), dividend up 6% to 17p Full announcement and CFO video available in …

Distribution channels: Companies

Published on April 20, 2012 - 12:10 GMT

GlaxoSmithKline reaches agreement to divest non-core over-the-counter (OTC) brands in international markets for £164 million

Issued: Friday 20 April 2012, London UK Announcement follows divestment of brands in USA, Canada & Europe GlaxoSmithKline Plc (GSK) today announced that it has reached agreement to divest the previously identified non-core OTC brands in its …

Distribution channels: Companies

Published on April 19, 2012 - 12:10 GMT

GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash

Issued: Thursday 19 April 2012, London UK - Transaction would deliver Human Genome Sciences shareholders immediate full value and certainty - Acquisition would give GSK full ownership of Benlysta, albiglutide and darapladib GlaxoSmithKline plc (LSE: …

Distribution channels: Companies

Published on April 11, 2012 - 14:22 GMT

GSK provides update on corporate responsibility commitments in 2011 report

Issued: Wednesday 11 April 2012, London UK GlaxoSmithKline (GSK) has today published its Corporate Responsibility Report , in which the company reiterates its commitment to operate responsibly, openly and transparently and sets out advances made …

Distribution channels: Companies

Published on April 3, 2012 - 06:10 GMT

GSK receives further data from phase lll studies of albiglutide in type 2 diabetes

Issued: Tuesday 03 April 2012, London, UK Data from seven studies support progression towards regulatory filings GlaxoSmithKline plc (GSK) today announced that topline results have been received from seven of the eight ‘Harmony’ Phase III studies …

Distribution channels: Companies

Published on April 2, 2012 - 12:10 GMT

GlaxoSmithKline to increase its ownership in Theravance

Issued: Monday 02 April 2012, London UK and South San Francisco, CA GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will …

Distribution channels: Companies

Published on April 2, 2012 - 06:10 GMT

Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV

Issued: Monday 02 April 2012, London, UK Press release issued by Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established by GlaxoSmithKline and Pfizer, Inc.) and Shionogi & Co., Ltd. …

Distribution channels: Companies

Published on March 23, 2012 - 13:10 GMT

GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® ...

Issued: Friday 23 March 2012, London UK and South San Francisco, CA, USA - COPD and asthma regulatory plans remain on track for submission from mid-2012 GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the registrational …

Distribution channels: Companies

Published on March 22, 2012 - 07:10 GMT

GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory

Issued: Wednesday 21 March 2012, London UK In total more than £500m of investment confirmed, creating up to 1,000 new jobs Includes £100m investment for GSK manufacturing in Scotland Options for further significant investment in UK manufacturing also …

Distribution channels: Companies

Published on March 20, 2012 - 17:12 GMT

GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas

Issued: Tuesday 20 March 2012, London UK & Philadelphia US GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk …

Distribution channels: Companies

Published on March 15, 2012 - 10:13 GMT

GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands

Issued: Thursday 15 March 2012, London UK - Agreement reached to divest brands in Europe to Omega Pharma for €470m (£391m) - Announcement follows divestment of brands in USA and Canada completed in January 2012 - Process continues for divesting brands in …

Distribution channels: Companies

Published on March 9, 2012 - 10:13 GMT

GSK reinforces commitment to youth training with launch of new UK apprenticeship programme

Issued: Friday 09 March 2012, London UK New scheme to offer 40 annual apprenticeships in manufacturing, R&D and IT with formal training & development programme GSK today announced the launch of a new multi-disciplinary apprenticeship scheme. The …

Distribution channels: Companies

Published on March 5, 2012 - 15:10 GMT

Regulatory Update: GSK announces submissions for two influenza vaccines

Issued: Monday 05 March 2012, London, UK GlaxoSmithKline [GSK] announced today that it has submitted regulatory files for two of its influenza vaccines currently in development. Quadrivalent influenza vaccine GSK has submitted US and EU …

Distribution channels: Companies

Published on March 2, 2012 - 00:10 GMT

GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan

Issued: Thursday 01 March 2012, London UK and Philadelphia, US GlaxoSmithKline (GSK) today announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vaccines company …

Distribution channels: Companies

Published on February 17, 2012 - 13:10 GMT

GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®

Issued: Friday 17 February 2012, London UK GlaxoSmithKline (GSK) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for …

Distribution channels: Companies

Published on February 16, 2012 - 17:11 GMT

EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)

Issued: Thursday 16 February 2012, London UK GlaxoSmithKline announced today that it has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib) and its use in combination with trastuzumab to treat patients with HER2 …

Distribution channels: Companies